ABSTRACT
Since the initial cases of the Coronavirus Disease in 2019 (COVID-19) occurred in Wuhan in December 2019, more and more cases have been found and confirmed, not only in central China but also in other countries. Given there are still no effective drugs many approved "old drugs" are in clinical test for treating COVID-19 at present. Artemisinin, a first-line antimalarial drug recommended by WHO, has been validated to possess a variety of pharmacological effects, including, without limitation, antiinflammatory, immune regulation, anti-pulmonary fibrosis, antibacterial, antiviral and cardiovascular effects, and the like. In this paper, various pharmacological effects of Artemisinin and its derivatives have been summarized, with the emphasis on the mechanism of action, so as to explore its potential medicinal value, especially for treating COVID-19.
ABSTRACT
Objective: To study the potential mechanism of Tankejing in the treatment of respiratory system based on network pharmacology, and to evaluate the possibility of Tankejing in the prevention and treatment of COVID-19 pneumonia.
ABSTRACT
As the number of discharged patients with novel coronavirus pneumonia (COVID-19) increased, TCM treatment received more attention. Some COVID-19 diagnosis and treatment plans issued by national health commission and local government recorded the syndrome differentiation and classification of TCM in the convalescent period and the treatment prescriptions. The clinical characteristics and TCM classification of convalescent period were also reported in recent literatures. Deficiency of Qi and Yin is the main syndrome in recovery period, and the Shengmai Powder (SMS) is the representative prescription. This paper reviews the studies of SMS in the treatment of deficiency of Qi and Yin, pulmonary fibrosis and vascular endothelial cell injury. The feasibility of SMS for the discharged patients with COVID-19 was discussed. This review will provide reference for clinical doctors and patients in the recovery period of TCM treatment.